Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

727.20 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Nov 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
The Smartest Megacap Growth ETF to Buy With $500 Right Now
Via The Motley Fool
Topics ETFs
Eli Lilly's Zepbound/Mounjaro Shows Cardiovascular Benefits In Patients With Obesity-Related Heart Failure
Eli Lilly's Phase 3 SUMMIT trial results show tirzepatide's potential to reduce heart failure risk and improve symptoms in obese adults with HFpEF. 
Via Benzinga
3 Growth Stocks You Can Buy Right Now Without Any Hesitation
Via The Motley Fool
If You Bought 1 Share of Eli Lilly in 1984, Here's How Many Shares You Would Own Now
Via The Motley Fool
Goldman Sachs Economist: Weight-Loss Drugs Could Be Key To US Economic Growth
A Goldman Sachs economist has suggested that the US economy could experience accelerated growth with increased use of GLP-1 weight-loss drugs like Ozempic. 
Via Benzinga
Topics Economy
Exposures Economy
Prediction: 3 Stocks That'll Be Worth More Than Tesla 10 Years From Now
These stocks have realistic paths to grow larger than Tesla. 
Via The Motley Fool
Eli Lilly Unusual Options Activity For November 13
Via Benzinga
Not-So-Big Pharma
Thanks to the change in the Health and Human Services Department, 'big pharma' stocks are one of the very few sectors in equity-land that are seemingly unhappy about the forthcoming administration. 
Via Talk Markets
Prediction: Acquisitions Will Skyrocket Under The Trump Administration. Here's 1 Pharmaceutical Company I Have My Eyes On.
Mergers and acquisitions could make a comeback with Trump headed back to Washington. 
Via The Motley Fool
Topics Government
Exposures Political
AskSlim Market Week - Friday, Nov. 15
An analysis and commentary on the financial markets. 
Via Talk Markets
Powell Speaks The Truth - Market Does Not Like It, Consternation About Kennedy, Gaetz, And Hegseth
To gain an edge, this is what you need to know today. 
Via Benzinga
Mounjaro-Maker Eli Lilly Files Lawsuit Against US Agency Over Drug Rebate Program
Eli Lilly proposed a plan to ensure 340B entities pay no more than the ceiling price by providing them with cash directly on a weekly basis. 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Should You Forget Eli Lilly and Buy This Magnificent Biotech Stock Instead?
Via The Motley Fool
99% Of Mounjaro/Zepbound Patients Remained Diabetes-Free Even At 3 Years, Eli Lilly's Detailed Phase 3 Data Shows
Eli Lilly's Phase 3 study shows tirzepatide significantly cuts type 2 diabetes risk and supports 22.9% average weight loss in adults over three years. 
Via Benzinga
Why Are These 3 Vanguard ETFs Underperforming the S&P 500 Since Election Day?
Stocks in these "safe" sectors are selling off as investors gravitate toward growth. 
Via The Motley Fool
Topics ETFs Stocks
Exposures US Equities
2 Top Growth Stocks to Buy on the Dip
Their recent issues are nothing to fret over for investors focused on the long game. 
Via The Motley Fool
3 Ultra-Safe Dividend Stocks That Have Been Paying Dividends for More Than 100 Years
These are income stocks you can buy and hold forever. 
Via The Motley Fool
Amgen Defends Its Investigational Monthly Weight Loss Injection After Analyst Cites MariTide's Impact on Bone Density
Amgen addresses safety concerns for its weight loss drug MariTide after new data suggests a potential 4% reduction in bone density at the highest dose. 
Via Benzinga
Did Viking Therapeutics Just Say "Checkmate" To Eli Lilly?
Viking Therapeutics just revealed a new plan that could make waves in the weight loss industry. 
Via The Motley Fool
Humanitarian Organization Criticizes Eli Lilly, Novo Nordisk And Sanofi Of Having 'Double Standards' For High Insulin Price
MSF calls for insulin manufacturers to provide $1 injection pens globally, emphasizing current high prices and limited access. Novo Nordisk's production shift raises concerns as diabetes cases rise,... 
Via Benzinga
2 S&P 500 Dividend Stocks That Could Soar 30% or More, According to a Pair of Wall Street Analysts
If Wall Street's right, investors will get a lot more than just rising dividend payments from this pair. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Jim Cramer Says Eli Lilly's 'Pathetic' Stock Performance Could Get A Breather If Amgen Has Hidden Bone Risk Data After 7% Stock Drop
Amgen Inc.'s stock dropped over 7% on Tuesday following revelations about bone density loss in early trials of its experimental obesity drug MariTide, while CNBC's Jim Cramer suggested the news could... 
Via Benzinga
Tradepulse Power Inflow Alert: Eli Lilly & Company Moves Up Over 13 Points After Signal
Via Benzinga
Amgen Drops 7% After A 'Big Unknown Risk' Rattles Its Monthly Obesity Shot
The company is testing MariTide as a monthly shot, rivaling weekly injections from Novo Nordisk and Eli Lilly. 
Via Investor's Business Daily
Bristol-Myers Squibb's $14 Billion Potential - Analyst Upgrades Stock
Leerink upgrades Bristol-Myers Squibb with an increased price target and strong sales projections for Cobenfy and milvexian, predicting significant stock outperformance. 
Via Benzinga
3 Top Stocks Crushing Q3 Earnings With Strong 2024 Guidance
Hims & Hers, Payoneer, and Astera Labs lead Q3 earnings with standout revenue growth, forecast upgrades, and strategic wins—stocks to watch for growth potential 
Via MarketBeat
Biotech Stocks Are Rallying: What Is Your Playbook?
If you have been reading our posts you know that some of the big biotech winners have taken a hit after earnings : LLY, MRK and REGN. But ABBV, GILD, LLY, and VRTX remain among the top performers. 
Via Talk Markets
Tesla Remains Core For Gary Black Despite Price Cuts, Earnings Drop — Nvidia, Google, Eli Lilly Among Top Performers In Tech Bull's Portfolio
Tesla remains a significant holding for The Future Fund despite position reductions, according to Managing Partner Gary Black, who cited concerns over the impact of electric vehicle price cuts on... 
Via Benzinga
Topics Electric Vehicles
Exposures Electric Vehicles
1 Stubborn Cloud and 2 Silver Linings for Eli Lilly Stock
Conditions are getting a bit more challenging for the drugmaker. 
Via The Motley Fool
Does This New Issue Threaten Eli Lilly and Novo Nordisk Shares?
The good times aren't over, but the peak of the party might be passing. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.